According to Nature, researchers are poised to meet with the FDA this month to discuss “medicines that delay ageing-related disease as legitimate drugs.” This makes sense, given that there are a number of scientific teams working on such compounds. Nir Barzilai of the Albert Einstein College of Medicine in New York is one of those scientists, and the compond he’s focused on is metformin, which has shown promise in previous studies.
FDA to consider anti-aging drugs